Meridian Life Science, Inc. is a wholly owned subsidiary of Meridian Bioscience, Inc.
Meridian Bioscience entered the life science market primarily through its acquisitions of:
- BIODESIGN International (a subsidiary of Gull Laboratories) in 1998
- Viral Antigens, Inc. in 2000
- OEM Concepts, Inc. in 2005
Meridian Life Science is a leading manufacturer and supplier of antibodies, viral antigens and critical assay reagents. We provide contract biologic R&D and manufacturing services to the diagnostic manufacturers along with cGMP biologics manufacturing for the biopharmaceutical market. We have been providing innovative life science solutions and building trusted partnerships for over 25 years. Our focus is to offer products and services that help to advance the diagnosis and treatment of disease.
Contract manufacturing of proteins and other biologicals for biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines is an example of significant new product applications built from Meridian Life Science’s existing expertise in manufacturing bulk antigens and reagents using cell culture techniques. This business focuses on cGMP contract manufacturing of materials that will be used in Phase I and II clinical trials.
The life science operating segment has targeted three primary market segments for its products and services:
- bulk biomedical reagents
- drug and vaccine discovery
- drug and vaccine development
The customer base for bulk biomedical reagents is large and fragmented, and includes some of the largest diagnostic manufacturers in the world as well as researchers in academia and the pharmaceutical and biotechnology industries. The market segments for drug and vaccine discovery and development are intended to be served via contract manufacturing.
The business strategy of Meridian Life Science includes the following: